Neoadjuvant PRRT With Y-90-DOTATOC in pNET

Stopped Difficulty in recruiting patients also due to the pandemic period, presence of competitive studies.

Conditions

• Pancreatic Neuroendocrine Tumor

Interventions

• DRUG: peptide receptor radionuclide therapy with Y-90-DOTATOC

Sponsor

European Institute of Oncology

Collaborators

• [object Object]